Third, while AKT3 and FGFR2 show potential as specific prognostic biomarkers for PPLELC patients rather than NSCLC patients, their validity requires confirmation through independent PPLELC cohorts. The gene discussed is AKT3; the disease is non-small cell lung carcinoma.